| Literature DB >> 35885638 |
Aleksander Zwierz1, Krzysztof Domagalski2, Krystyna Masna1, Paweł Burduk1.
Abstract
OBJECTIVES: To demonstrate the effectiveness of endoscopic assessment of the pharyngeal tonsil in defining the size of the adenoid hypertrophy in endoscopic examination that would be equivalent to intraoperative assessment as a large adenoid, and to determine the lowest necessary frequency of tests to assess the variability of its size.Entities:
Keywords: adenoid hypertrophy; adenoid size; adenoidectomy indications; flexible nasofiberoscopy
Year: 2022 PMID: 35885638 PMCID: PMC9316505 DOI: 10.3390/diagnostics12071734
Source DB: PubMed Journal: Diagnostics (Basel) ISSN: 2075-4418
Figure 1Intraoperative adenoid size measurement.
Patients’ characteristics in the whole first group who underwent adenoidectomy and according to gender.
| Characteristics | All Patients | Female | Male | ||
|---|---|---|---|---|---|
|
| 108 | 43 | 65 | ||
| Gender | female | 43 (39.8%) | 43 (39.8%) | - | |
| male | 65 (60.2%) | 65 (60.2%) | |||
| Age (years) | mean ± | 5.2 ± 1.8 | 5.4 ± 1.9 | 5.0 ± 1.7 | 0.267 |
| median (Q25–Q75) | 5.0 (4.0–6.0) | 5.0 (4.0–6.0) | 4.5 (4.0–5.5) | ||
| Adenoid size (A/C ratio *, %) | mean ± | 77.5 ± 13.2 | 78.8 ± 13.4 | 76.6 ± 13.2 | 0.396 |
| median (Q25–Q75) | 80.0 (75.0–85.0) | 80.0 (75.0–90.0) | 80.0 (70.0–85.0) | ||
| 40 | 1 (0.9%) | 1 (2.3%) | 0 (0.0%) | 0.505 | |
| 50 | 10 (9.3%) | 2 (4.7%) | 8 (12.3%) | ||
| 60 | 9 (8.3%) | 4 (9.3%) | 5 (7.7%) | ||
| 65 | 3 (2.8%) | 1 (2.3%) | 2 (3.1%) | ||
| 70 | 3 (2.8%) | 1 (2.3%) | 2 (3.1%) | ||
| 75 | 13 (12.0%) | 7 (16.3%) | 6 (9.2%) | ||
| 80 | 23 (21.3%) | 7 (16.3%) | 16 (24.6%) | ||
| 85 | 22 (20.4%) | 7 (16.3%) | 15 (23.1%) | ||
| 90 | 16 (14.8%) | 8 (18.6%) | 8 (12.3%) | ||
| 95 | 8 (7.4%) | 5 (11.6%) | 3 (4.6%) | ||
| Adenoid size (A/C ratio on Bolesławska scale, %) | 35–65 (B II) | 23 (21.3%) | 8 (18.6%) | 15 (23.1%) | 0.587 |
| >65 (B III) | 85 (78.7%) | 35 (81.4%) | 50 (76.9%) | ||
| Operative adenoid size, 3 categories | small | 21 (19.4%) | 8 (18.6%) | 13 (20.0%) | 0.857 |
| medium | 12 (11.1%) | 6 (14.0%) | 6 (9.2%) | ||
| large | 75 (69.4%) | 29 (67.4%) | 46 (70.8%) | ||
| Operative adenoid size, 2 categories | not large | 33 (30.6%) | 14 (32.6%) | 19 (29.2%) | 0.713 |
| large | 75 (69.4%) | 29 (67.4%) | 46 (70.8%) | ||
| Consistency between A/C ratio in Bolesławska scale and operative adenoid size ** | true | 96 (88.9%) | 37 (86.0%) | 59 (90.8%) | 0.536 |
| false | 12 (11.1%) | 6 (14.0%) | 6 (9.2%) |
* A/C ratio—adenoid-to-choana ratio. ** Consistency when second degree in the Bolesławska scale (B II) = not large operative adenoid size (small and medium) or B III = large operative adenoid size.
Association between macroscopic adenoid size and demographic variables and A/C ratio.
| Characteristics | Operative Adenoid Size, 3 Categories | ||||
|---|---|---|---|---|---|
| Small | Medium | Large | |||
|
| 21 | 12 | 75 | ||
| Gender | |||||
| female | 8 (38.1%) | 6 (50.0%) | 29 (38.7%) | 0.857 | 0.713 |
| male | 13 (61.9%) | 6 (50.0%) | 46 (61.3%) | ||
| Age (years) | |||||
| mean ± | 5.0 ± 1.5 | 4.7 ± 1.3 | 5.3 ± 1.9 | 0.559 | 0.336 |
| median (Q25–Q75) | 4.5 (4.0–6.5) | 4.3 (4.0–5.8) | 5.0 (4.0–6.0) | ||
| Adenoid size (A/C ratio, %) | |||||
| mean ± | 59.5 ± 13.6 | 69.6 ± 10.1 | 83.8 ± 6.8 | <0.001 3 | <0.001 |
| median (Q25–Q75) | 50.0 (50.0–65.0) | 67.5 (60.0–77.5) | 85.0 (80.0–90.0) | ||
| Adenoid size (A/C ratio on Bolesławska scale, %) | |||||
| 35–65 (B II) | 16 (76.2%) | 6 (50.0%) | 1 (1.3%) | <0.001 | <0.001 |
| >65 (B III) | 5 (23.8%) | 6 (50.0%) | 74 (98.7%) | ||
| Consistency between A/C ratio on Bolesławska scale and operative adenoid size | |||||
| true | 16 (76.2%) | 6 (50.0%) | 74 (98.7%) | <0.001 | <0.001 |
| false | 5 (23.8%) | 6 (50.0%) | 1 (1.3%) | ||
1 p value for comparison of small vs. medium vs. large adenoid size; 2 p value for comparison of not large (small + medium) vs. large adenoid size. 3 Bonferroni post hoc tests: small vs. medium, p = 0.007; medium vs. large, p < 0.001; small vs. large, p < 0.001.
Figure 2Diagnostic accuracy of A/C ratio for diagnosis of large operative adenoid size.
Diagnostic value of A/C ratio for diagnosis of large operative adenoid size.
| A/C Ratio | ||
|---|---|---|
|
| 0.894 | |
|
| 0.818–0.969 | |
|
| <0.001 | |
|
| 75.0 | 80.0 |
|
| 97.3% | 84.0% |
|
| 72.7% | 81.8% |
|
| 89.0% | 91.3% |
|
| 92.3% | 69.2% |
AUC—area under the curve. 95% CI—95% confidence interval. PPV—positive predictive value. NPV—negative predictive value.
Characteristics of the group of patients undergoing long-term observation.
| Characteristics | All Patients | |
|---|---|---|
|
| 81 | |
| Gender | female | 43 (53.1%) |
| male | 38 (46.9%) | |
| Age at the first visit (years) | mean ± | 3.9 ± 1.2 |
| median (Q25–Q75) | 3.5 (3.0–4.5) | |
| Number of measurements | 3 | 47 (58.0%) |
| 4 | 16 (19.8%) | |
| 5 | 15 (18.5%) | |
| 6 | 2 (2.5%) | |
| 7 | 1 (1.2%) | |
| Period of observation (years) | mean ± | 2.4 ± 1.2 |
| median (Q25–Q75) | 2.0 (1.5–3.0) | |
| 1–3 | 63 (77.8%) | |
| 3.5–5.5 | 18 (22.2%) | |
| First visit | mean ± | 65.4 ± 13.2 |
| median (Q25–Q75) | 65.0 (55.0–75.0) | |
| Bolesławska scale | <35 | 1 (1.2%) |
| 35–65 | 46 (56.8%) | |
| >65 | 34 (42.0%) | |
| Last visit | mean ± | 61.2 ± 16.1 |
| median (Q25–Q75) | 60.0 (50.0–75.0) | |
| Bolesławska scale | <35 | 4 (4.9%) |
| 35–65 | 46 (56.8%) | |
| >65 | 31 (38.3%) | |
| Change; first vs. last visit | decrease | 21 (25.9%) |
| no change | 17 (21.0%) | |
| increase | 43 (53.1%) | |
| ≤10 | 54 (66.7%) | |
| >10 | 27 (33.3%) | |
| ≤15 | 61 (75.3%) | |
| >15 | 20 (24.7%) | |
| Max | mean ± | 71.0 ± 12.3 |
| median (Q25–Q75) | 70.0 (60.0–80.0) | |
| Min | mean ± | 56.3 ± 14.6 |
| median (Q25–Q75) | 55.0 (50.0–70.0) | |
| Range | mean ± | 14.7 ± 11.2 |
| median (Q25–Q75) | 10.0 (5.0–20.0) | |
| ≤10 | 42 (51.9%) | |
| >10 | 39 (48.1%) | |
| ≤15 | 56 (69.1%) | |
| >15 | 25 (30.9%) | |
| Semi-annual continuous measurements, 1 year |
| 38 (46.9%) |
| Range | ≤10 | 28 (73.7%) |
| >10 | 10 (26.3%) | |
| ≤15 | 35 (92.1%) | |
| >15 | 3 (7.9%) | |
| Annual continuous measurements (at least one measurement per year) |
| 57 (70.4%) |
| Range | ≤10 | 34 (59.6%) |
| >10 | 23 (40.4%) | |
| ≤15 | 42 (73.7%) | |
| >15 | 15 (26.3%) | |
| Two-year period |
| 37 (45.7%) |
| Range | ≤10 | 21 (56.8%) |
| >10 | 16 (43.2%) | |
| ≤15 | 29 (78.4%) | |
| >15 | 8 (21.6%) | |
| Three-year period |
| 20 (24.7%) |
| Range | ≤10 | 7 (35.0%) |
| >10 | 13 (65.0%) | |
| ≤15 | 11 (55.0%) | |
| >15 | 9 (45.0%) |
Figure 3Schema of frequency of adenoid examinations and treatment.